How Clinical Trials Work

Clinical trials can provide strong evidence, but only when the question, comparison, outcomes, analysis and safeguards are clear. Phase labels apply mainly to medicines, and no single trial removes uncertainty.

What a clinical trial is A clinical trial is an interventional study involving people. Researchers assign an intervention and measure defined outcomes to learn about possible benefits and harms. Trials can test medicines, vaccines, devices, procedures, rehabilitation, psychological treatments or ways of organising care. Not every clinical trial is randomised, blinded or divided into phases. Phase 1 to Phase 4 labels are used mainly during medicine and vaccine development. Trials of surgery, devices or service changes may use different descriptions and designs. Before a new medicine reaches human trials, researchers usually complete laboratory, manufacturing and non clinical work. These steps cannot prove how the medicine will behave in people. The protocol comes before the result A trial protocol is the written plan for the study. It defines the research question, eligible participants, intervention, comparator, outcomes, follow up, safety procedures and analysis. Eligibility criteria state who can and cannot enter. They protect participants and create a clear study population, but narrow criteria can limit how widely the result applies. The primary outcome is the main result chosen to answer the trial question. It should be specified before researchers know the results. Secondary outcomes can add useful information but need cautious interpretation, especially when many are tested. Changing the main outcome after seeing the data can create a misleading impression. Public trial registration and access to the protocol help readers identify unplanned changes or missing results. A comparison is essential People may improve because of natural recovery, other treatment, changes in behaviour or ordinary symptom fluctuation. Measurements and reporting can also change over time. A comparator helps estimate what would have happened under the alternative being compared. It may be standard treatment, another active treatment, usual care, a placebo or no added intervention. A placebo is designed to resemble an intervention without containing its specific active component. Some trials use a sham procedure rather than a placebo medicine. These comparisons require scientific and ethical justification. A placebo response is the change observed in people receiving placebo. It can include natural recovery, symptoms returning towards their usual level, additional care, reporting effects and treatment context effects. The specific placebo effect is only one possible part of that response. Improvement in a placebo group should not all be attributed to belief. A placebo or no treatment group is not automatically ethical. It may be acceptable when no proven intervention exists or when there is a sound reason and participants are not exposed to serious or irreversible harm. Randomisation does not guarantee identical groups Randomisation uses an unpredictable sequence to assign participants to trial groups. It reduces selection bias and tends to balance important differences between groups on average. One individual trial can still have imbalances, especially when it is small. Randomisation does not guarantee equal ages, conditions or risks in every group. Allocation concealment protects the random sequence before each assignment. The person enrolling a participant should not be able to predict or change the next group. Randomisation and allocation concealment solve different problems. A random sequence can still be undermined if recruiters know upcoming assignments. Blinding reduces some forms of bias Blinding means keeping specified people unaware of the assigned intervention after allocation. Those people may include participants, treating professionals, outcome assessors or data analysts. The labels single blind and double blind are used inconsistently. A clear report should state exactly who was blinded and how the blinding was maintained. Blinding can reduce differences in care, reporting and outcome assessment. It is not always possible, especially in trials of surgery, rehabilitation or service delivery. An unblinded trial is not automatically invalid. It needs other safeguards, such as standardised care, objective outcomes and blinded assessment where practical. Medicine trials may use phases Phase 1 trials are early human studies. They usually focus on dose, tolerability, how the body handles the medicine and early safety information. Participants may be healthy volunteers or patients, depending on the treatment. Phase 2 trials explore dose, biological activity or early evidence of benefit while continuing safety assessment. They may be randomised or non randomised. Phase 3 trials usually provide a larger confirmatory comparison in the intended patient population. They estimate benefits and harms against standard care or another justified comparator. Phase 4 trials take place after authorisation and examine questions such as longer term effects, wider use or new approved uses. Wider post authorisation safety surveillance is not limited to Phase 4 trials. Development does not always follow four separate steps. Trials can combine phases, adapt pre specified features or stop development when results do not support continuing. Consent and oversight protect participants Participation should be voluntary and based on understandable information. People need to know the purpose, procedures, possible benefits, risks, alternatives, data use and practical commitments. A participant can usually stop the trial intervention or withdraw from further participation without losing ordinary care. An intervention already received cannot be undone. Information already collected may still be retained or analysed under the approved plan. The consent discussion should explain the withdrawal options clearly before enrolment. In the UK, a clinical trial of an investigational medicine normally needs MHRA authorisation and a favourable Research Ethics Committee opinion before it starts. The sponsor has overall responsibility for trial design, management, quality and safety systems. Investigators are responsible for conduct and participant care at their trial sites. Some trials use an independent data monitoring committee to review accumulating information. Not every trial needs one, and a Research Ethics Committee does not conduct the trial's day to day safety monitoring. An adverse event is an unwanted medical occurrence during a trial. It does not automatically mean the intervention caused it. An adverse reaction involves a suspected causal relationship. Trials may stop early for harm, clear benefit, little realistic chance of worthwhile benefit or practical reasons. Planned checks of accumulating data and stopping rules reduce premature decisions from temporary patterns. Read the whole trial, not one headline A trustworthy report states how many people were assigned, treated, followed and included in each analysis. Missing outcomes and unequal withdrawal can distort the comparison. An intention to treat analysis usually compares participants in the groups to which they were randomised. This helps preserve the original randomised comparison, although missing data can still cause problems. Readers should check the pre specified primary outcome and effect size, which shows how large the difference was. The confidence interval shows statistical uncertainty, while adverse events describe possible harms. They should also compare the publication with the trial registration and protocol. Funding and conflicts of interest should be reported. Industry funding does not automatically invalidate a result, but methods, analysis and reporting still require careful scrutiny. One positive trial is rarely the whole answer. Decisions may use one or more major trials together with replication, reviews of multiple studies, other safety evidence and relevance to the people receiving treatment. Regulatory authorisation means the available evidence supported a favourable balance of benefits and harms for a defined use. It does not mean the treatment works for everyone or that every rare harm is already known.

A trustworthy trial begins with a pre specified question and ends with complete, transparent reporting. Randomisation reduces bias, but methods, missing data, harms and applicability still matter.